Physician profile
Boning Li
NPI 1821454471
$2,642.49
in general payments reported to CMS, 2019-2025
22 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $192 · 2021: $126 · 2022: $524 · 2023: $638 · 2024: $335 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $796.87 | 2020-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $565.66 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.07 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $233.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $126.95 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $99.99 | 2019 | |
| Viatris Specialty LLC | $98.19 | 2025 | Yupelri |
| Pulmonx Corporation | $92.28 | 2022 | |
| Harmony Biosciences LLC | $57.62 | 2024-2025 | |
| Philips North America LLC | $52.00 | 2020-2025 | Vest Therapy Und |
| United Therapeutics Corporation | $31.12 | 2024-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $28.66 | 2020-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $27.17 | 2019-2020 | |
| Baxter Healthcare | $24.77 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Avadel Cns Pharmaceuticals, LLC | $19.92 | 2025 | Lumryz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $19.50 | 2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $18.11 | 2025 | |
| Insmed, INC. | $17.79 | 2025 | Arikayce |
| Axsome Therapeutics, INC. | $17.73 | 2025 | Sunosi |
| Verona Pharma, INC. | $15.27 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $14.97 | 2020 | |
| Veran Medical Technologies, INC. | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boning Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.